<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Biol Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Biol Psychiatry</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Biological psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0006-3223</issn><issn pub-type="epub">1873-2402</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10884738</article-id><article-id pub-id-type="pmcid-ver">PMC10884738.319</article-id><article-id pub-id-type="pmcaid">10884738</article-id><article-id pub-id-type="pmcaiid">10884738</article-id><article-id pub-id-type="manuscript-id">NIHMS1924151</article-id><article-id pub-id-type="pmid">37573004</article-id><article-id pub-id-type="doi">10.1016/j.biopsych.2023.08.004</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1924151</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1924151</article-id><article-version article-version-type="pmc-version">319</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Clinical and preclinical evidence for gut microbiome mechanisms in
substance use disorder</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Hofford</surname><given-names initials="RS">Rebecca S.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kiraly</surname><given-names initials="DD">Drew D.</given-names></name><degrees>MD, PhD</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Physiology &amp; Pharmacology, Wake Forest
University School of Medicine, Atrium Wake Forest Baptist Health, Winston-Salem,
North Carolina 27101, United States</aff><aff id="A2"><label>2</label>Department of Psychiatry, Wake Forest University School of
Medicine, Atrium Wake Forest Baptist Health, Winston-Salem, North Carolina 27101,
United States</aff><author-notes><corresp id="CR1"><label>*</label>To whom correspondence should be addressed: Drew
D. Kiraly, MD, PhD, Associate Professor Physiology, Pharmacology &amp;
Psychiatry, Wake Forest School of Medicine, Atrium Health Wake Forest Baptist,
115 S. Chestnut Street, Winston-Salem, NC 27104,
<email>dkiraly@wakehealth.edu</email>, Twitter: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://twitter.com/kiralylab" ext-link-type="uri">@kiralylab</ext-link></corresp><fn fn-type="COI-statement" id="FN1"><p id="P31">Disclosures</p><p id="P32">The authors report no biomedical financial interests or potential
conflicts of interest.</p></fn></author-notes><pub-date pub-type="ppub"><day>15</day><month>2</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>10</day><month>8</month><year>2023</year></pub-date><volume>95</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">456324</issue-id><fpage>329</fpage><lpage>338</lpage><pub-history><event event-type="nihms-submitted"><date><day>15</day><month>08</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>15</day><month>02</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>15</day><month>02</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-02-15 13:25:27.897"><day>15</day><month>02</month><year>2025</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1924151.pdf"/><abstract id="ABS1"><p id="P1">Substance use disorders are a set of recalcitrant neuropsychiatric
conditions that cause tremendous amounts of morbidity and mortality and are
amongst the leading causes of loss of disability adjusted life years worldwide.
While each specific substance use disorder is driven by problematic use of a
different substance, they all share a similar pattern of escalating and out of
control substance use, continued use despite negative consequences, and a
remitting/relapsing pattern over time. Despite significant advances in our
understanding of the neurobiology of these conditions, current treatment options
remain few and are ineffective for too many. In recent years, there has been a
rapidly growing body of literature demonstrating that the resident population of
microbes in the gastrointestinal tract, collectively called the gut microbiome,
plays an important role in modulating brain and behavior in preclinical and
clinical studies of psychiatric disease. While these findings have not yet been
translated to clinical practice, this remains an important and exciting avenue
for translational research. In this review, we will highlight the current state
of microbiome-brain research within the substance use field with a focus on both
clinical and preclinical studies. We also discuss potential neurobiological
mechanisms underlying microbiome effects on models of substance use disorder and
propose future directions to bring these findings from bench to bedside.</p></abstract><kwd-group><kwd>Microbiome</kwd><kwd>Substance use disorder</kwd><kwd>Alcohol use disorder</kwd><kwd>Neuroimmune</kwd><kwd>Gut-brain</kwd><kwd>Epigenetics</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>